CD38 Targeted -PET/ CT for Multiple Myeloma
Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma
1 other identifier
interventional
100
1 country
1
Brief Summary
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2026
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 7, 2026
CompletedFirst Submitted
Initial submission to the registry
August 20, 2026
CompletedFirst Posted
Study publicly available on registry
August 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2030
August 24, 2026
July 1, 2026
4.5 years
August 20, 2026
August 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic efficacy
The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
3 year
Secondary Outcomes (2)
Number of lesions
3 year
SUV
3 year
Study Arms (1)
CD38 PET/CT
EXPERIMENTALEach subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET/CT imaging within the specified time.
Interventions
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.
Eligibility Criteria
You may qualify if:
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
You may not qualify if:
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affliated Hospital of Guilin Medical University
Guilin, Guangxi, 541001, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Nuclear Medicine
Study Record Dates
First Submitted
August 20, 2026
First Posted
August 24, 2026
Study Start
July 7, 2026
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
August 24, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share